Skip to main content Accessibility help
  • Print publication year: 2006
  • Online publication date: September 2009

4 - Surgical Management of Patients with Epithelial Ovarian Cancer

Related content

Powered by UNSILO
Jemal, A., Tiwari, R. C., Murray, T., et al. American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin (2004), 54:8–29.
Benedet, J. L., Hacker, N. F. and Ngan, H. Y. S., eds. Staging Classifications and Clinical Practice Guidelines of Gynaecological Cancers, 2nd Edition. FIGO Committee on Gynecologic Oncology and IGCS Guidelines Committee, 2003. Reprinted from Int J Gynecol Obstet (2000), 70:207–312.
Young, R. C., Decker, D. G., Wharton, J. T., et al. Staging laparotomy in early ovarian cancer. JAMA (1983), 250:3072–6.
Soper, J. T., Johnson, P., Johnson, V., et al. Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma. Obstet Gynecol (1992), 80:949–53.
Eisenkop, S. M. and Spirtos, N. M.. The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer. Gynecol Oncol (2001), 82:143–9.
Morice, P., Joulie, F., Camatte, S., et al. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. Am Coll Surg (2003), 197:198–205.
Trimbos, J. B., Vergote, I., Bolis, G., et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst (2003), 95:113–25.
Griffiths, C. T.. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr (1975), 42:101–4.
Prefontaine, M., Gelfand, A. T., Donovan, J. T. and Powell, J. L.. Reproducibility of tumor measurements in ovarian cancer: a study of interobserver variability. Gynecol Oncol (1994), 55:87–90.
Hoskins, W. J., McGuire, W. P., Brady, M. F., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol (1994), 170:974–9.
Hunter, R. W., Alexander, N. D. and Soutter, W. P.. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?Am J Obstet Gynecol (1992), 166:504–11.
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol (2002), 20:1248–59.
Eisenkop, S. M., Friedman, R. L. and Wang, H. J.. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol (1998), 69:103–8.
Allen, D. G. and Coulter, J.. Survival of patients with epithelial ovarian cancer and the effect of lymphadenectomy in those with stage 3 disease. Aust NZ J Obstet Gynaecol (1999), 39:420–4.
Kikkawa, F., Ishikawa, H., Tamakoshi, K., et al. Prognostic evaluation of lymphadenectomy for epithelial ovarian cancer. J Surg Oncol (1995), 60:227–31.
Yokoyama, Y., Sakamoto, T., Sato, S., et al. Evaluation of cytoreductive surgery with pelvic and paraaortic lymphadenectomy and intermittent cisplatin-based combination chemotherapy for improvement of long-term survival in ovarian cancer. Eur J Gynaecol Oncol (1999), 20:361–6.
Benedetti-Panici, B., Maggioni, A., Hacker, N., et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst (2005), 97:560–6.
Kehoe, S., Powell, J., Wilson, S., et al. The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma. Br J Cancer (1994), 70:1014–17.
Nguyen, H. N., Averette, H. E., Hoskins, W., et al. National survey of ovarian carcinoma. Part V. The impact of physician's specialty on patients' survival. Cancer (1993), 72:3663–70.
Giede, K. C., Kieser, K., Dodge, J., et al. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol (2005), 99:447–61.
Junor, E. J., Hole, D. J., McNulty, L., et al. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1,866 patients. Br J Obstet Gynaecol (1999), 106:1130–6.
Junor, E. J., Hole, D. J. and Gillis, C. R.. Management of ovarian cancer: referral to a multidisciplinary team matters. Br J Cancer (1994), 70:363–70.
Covens, A. L.. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol (2000), 78:269–74.
Hacker, N. F., Berek, J. S., Lagasse, L. D., et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol (1983), 61:413–20.
Hoskins, W. J., Bundy, B. N., Thigpen, J. T., et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol (1992), 47:159–66.
Crawford, S. C., Vasey, P. A., Paul, J., et al. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol (2005), 23:8802–11.
Vasey, P. A., Jayson, G. C., Gordon, A., et al. Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst (2004), 96:1682–91.
Brockbank, E. C., Ind, T. E., Barton, D. P., et al. Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer. Int J Gynecol Cancer (2004), 14:42–50.
Jacob, J. H., Gershenson, D. M., Morris, M., et al. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol (1991), 42:146–50.
Onnis, A., Marchetti, M., Padovan, P., et al. Neoadjuvant chemotherapy in advanced ovarian cancer. Eur J Gynaecol Oncol (1996), 17:393–6.
Schwartz, P. E., Rutherford, T. J., Chambers, J. T., et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol (1999), 72:93–9.
Ushijima, K., Ota, S., Komai, K., et al. Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer. Int Surg (2002), 87:185–90.
Vrscaj, M. U. and Rakar, S.. Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study. Eur J Gynaecol Oncol (2002), 23:405–10.
Kuhn, W., Rutke, S., Spathe, K., et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer (2001), 92:2585–91.
Vergote, I. B., Wever, I., Decloedt, J., et al. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol (2000), 27 (Suppl 7):31–6.
Vergote, I., Wever, I., Tjalma, W., et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol (1998), 71:431–6.
Volz, J., Koster, S., Spacek, Z., et al. The influence of pneumoperitoneum used in laparoscopic surgery on an intraabdominal tumor growth. Cancer (1999), 86:770–4.
Abu-Rustum, N. R., Sonoda, Y., Chi, D. S., et al. The effects of CO2 pneumoperitoneum on the survival of women with persistent metastatic ovarian cancer. Gynecol Oncol (2003), 90:431–4.
Abu-Rustum, N. R., Rhee, E. H., Chi, D. S., et al. Subcutaneous tumor implantation after laparoscopic procedures in women with malignant disease. Obstet Gynecol (2004), 103:480–7.
Nagarsheth, N. P., Rahaman, J., Cohen, C. J., et al. The incidence of port-site metastases in gynecologic cancers. JSLS (2004), 8:133–9.
Cavina, E., Goletti, O., Molea, N., et al. Trocar site tumor recurrences. May pneumoperitoneum be responsible?Surg Endosc (1998), 12:1294–6.
Dowdy, S. C., Mullany, S. A., Brandt, K. R., et al. The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer (2004), 101:346–52.
Everett, E. N., Heuser, C. C., Pastore, L. M., et al. Predictors of suboptimal surgical cytoreduction in women treated with initial cytoreductive surgery for advanced stage epithelial ovarian cancer. Am J Obstet Gynecol (2005), 193:568–74.
Qayyum, A., Coakley, F. V., Westphalen, A. C., et al. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol (2005), 96:301–6.
Bristow, R. E., Duska, L. R., Lambrou, N. C., et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer (2000), 89:1532–40.
Nelson, B. E., Rosenfield, A. T. and Schwartz, P. E.. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol (1993), 11:166–72.
Forstner, R., Hricak, H., Occhipinti, K. A., et al. Ovarian cancer: staging with CT and MR imaging. Radiology (1995), 197:619–26.
Burg, M. E., Lent, M., Buyse, M., et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med (1995), 332:629–34.
Rose, P. G., Nerenstone, S., Brady, M. F., et al. Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med (2004), 351:2489–97.
Harter, P. and Bois, A. du. The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence. Curr Opin Oncol (2005), 17:505–14.
Eisenkop, S. M., Friedman, R. L. and Spirtos, N. M.. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer (2000), 88:144–53.
Dvoretsky, P. M., Richards, K. A., Angel, C., et al. Survival time, causes of death, and tumor/treatment-related morbidity in 100 women with ovarian cancer. Hum Pathol (1988), 19:1273–9.
Tunca, J. C., Buchler, D. A., Mack, E. A., et al. The management of ovarian-cancer-caused bowel obstruction. Gynecol Oncol (1981), 12:186–92.
Pothuri, B., Vaidya, A., Aghajanian, C., et al. Palliative surgery for bowel obstruction in recurrent ovarian cancer: an updated series. Gynecol Oncol (2003), 89:306–13.
Feuer, D. J., Broadley, K. E., Shepherd, J. H., et al. Systematic review of surgery in malignant bowel obstruction in advanced gynecological and gastrointestinal cancer. The Systematic Review Steering Committee. Gynecol Oncol (1999), 75:313–22.
Krebs, H. B. and Goplerud, D. R.. Surgical management of bowel obstruction in advanced ovarian carcinoma. Obstet Gynecol (1983), 61:327–30.
Vera-Garcia, C.. A patient's perspective on ovarian cancer as a chronic disease – devaluing a survivor's challenge. Gynecol Oncol (2005), 96:19–20.